Product Reports Resources Pricing Login Book a demo
Greg Winter
Person deep dive

Greg Winter

Sir Greg Winter is a Cambridge biochemist who shared the 2018 Nobel Prize in Chemistry for his work on antibody drugs. He co-founded Cambridge Antibody Technology, bought by AstraZeneca for £702M in 2006, Domantis, bought by GlaxoSmithKline for £230M in 2006, and Bicycle Therapeutics, listed on Nasdaq in 2019.

Founded
Immutrin, Bicycle Therapeutics, Domantis +1 more
Education
University of Cambridge

Track record

Companies Greg Winter founded or backed, with what became of them.

Career

  1. 1973Graduated in natural sciences from Trinity College, Cambridge.
  2. 1981Became a group leader at the MRC Laboratory of Molecular Biology in Cambridge.
  3. 1986Developed the technique to humanise antibodies, the basis of many antibody drugs.
  4. 1989Co-founded Cambridge Antibody Technology, which discovered the antibody later sold by Abbott as Humira.
  5. 2000Founded Domantis to develop drugs from small antibody fragments.
  6. 2004Was knighted.
  7. 2006AstraZeneca bought Cambridge Antibody Technology for £702M, and GlaxoSmithKline bought Domantis for £230M.
  8. 2009Co-founded Bicycle Therapeutics.
  9. 2012Became Master of Trinity College, Cambridge, a post he held until 2019.
  10. 2018Shared the Nobel Prize in Chemistry with Frances Arnold and George Smith.
  11. 2019Bicycle Therapeutics listed on Nasdaq, raising about $60.7M.

Sources: Wikipedia: Greg Winter · Wikipedia: Cambridge Antibody Technology · Global Venturing: Bicycle Therapeutics squares $60.7m IPO circle · EPFL: Bicycle Therapeutics floats on Nasdaq · Dealroom: Greg Winter.

Companies founded

Work history

Past roles by Dealroom records.

MRC Laboratory of Molecular Biology
1973 – 2012

Education

University of Cambridge
Natural Sciences · until 1973
← All people